Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Receives $3.2M Milestone from GSK Under Vaccine Collaboration

Premium

Alnylam Pharmaceuticals this week announced that it has received a $3.2 million milestone payment from GlaxoSmithKline related to the companies' collaboration on influenza vaccine production.

Late last year, Alnylam unveiled an initiative focused on applying its RNAi technology to the production of vaccines (GSN 11/3/2011). It also said that GlaxoSmithKline had signed on as its first partner under the effort.

This week, Alnylam said that the partnership is initially on influenza vaccine production in cell culture systems, and that GlaxoSmithKline is obligated to provide research funding and certain milestones. GlaxoSmithKline also has an option to apply the RNAi technology to two additional vaccine products.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.